mRNA cancer vaccines:Advances,trends and challenges

查看全文 作　　者：Qing [1]He;Hua [1]Gao;Dejiang [1]Tan;Heng [1]Zhang;Jun-zhi [1]Wang

机构地区：[1]National Institutes for Food and Drug Control,State Key Laboratory for Evaluation and Standardization of Innovative Vaccines and Biotechnology Products,Beijing 102629,China

出　　处：《Acta Pharmaceutica Sinica B》索引2022年第12卷第7期,共21页

摘　　要：Patients exhibit good tolerance to messenger ribonucleic acid(m RNA)vaccines,and the choice of encoded molecules is flexible and diverse.These vaccines can be engineered to express full-length antigens containing multiple epitopes without major histocompatibility complex(MHC)restriction,are relatively easy to control and can be rapidly mass produced.In 2021,the U.S.Food and Drug Administration(FDA)approved the first m RNA-based coronavirus disease 2019(COVID-19)vaccine produced by Pfizer and Bio NTech,which has generated enthusiasm for m RNA vaccine research and development.Based on the above characteristics and the development of m RNA vaccines,m RNA cancer vaccines have become a research hotspot and have undergone rapid development,especially in the last five years.This review analyzes the advances in m RNA cancer vaccines from various perspectives,including the selection and expression of antigens/targets,the application of vectors and adjuvants,different administration routes,and preclinical evaluation,to reflect the trends and challenges associated with these vaccines. 关键词：MRNA Cancer vaccine Tumor-associated antigens Neoantigens mRNA delivery vectors ADJUVANTS Administration routes

相关文献

参考文献（194）
引证文献（20）
耦合文献（19）

参考文献(194)

引证文献(20)

耦合文献(19)

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

mRNA cancer vaccines:Advances,trends and challenges

参考文献(194)

引证文献(20)

耦合文献(19)

用户提示